Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.
暂无分享,去创建一个
C. Allegra | T. George | Dennie V. Jones | M. Markham | Ji Hyun Lee | P. Hosein | B. Ramnaraign | S. Staal | D. DeRemer | J. Close | A. Franke | K. Daily | M. Murphy | Nkiruka Ezenwajiaku | S. Rogers | Derek Li | J. Chatzkel